Recombinant human growth hormone therapy in HIV-associated wasting and visceral adiposity

Expert Review of Anti-Infective Therapy

Volumn 3, Issue 5, 2005, Pages 727-738

  Yin, Michael T ^a   Glesby, Marshall J ^b  

^a NewYork Presbyterian Hospital   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

HIV; Recombinant human growth hormone; Visceral adiposity; Wasting

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ABACAVIR; ANTIRETROVIRUS AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ARGININE; CD4 ANTIGEN; FATTY ACID; GHRELIN; GLUCOSE; GROWTH HORMONE RELEASING FACTOR; GROWTH HORMONE SECRETAGOGUE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HUMAN GROWTH HORMONE; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITROGEN; PLACEBO; PROTEINASE INHIBITOR; RECOMBINANT SOMATOMEDIN C; SERMORELIN; SOMATOMEDIN C; SOMATOSTATIN; SOMATREM; STAVUDINE; TH 9507; TRIACYLGLYCEROL; UNINDEXED DRUG; VIRUS RNA; ZIDOVUDINE;

ADIPOSE TISSUE; ARTHRALGIA; BLOOD TOXICITY; BODY FAT; BODY WEIGHT; CARPAL TUNNEL SYNDROME; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; FLUID RETENTION; GLUCONEOGENESIS; GLUCOSE HOMEOSTASIS; GLUCOSE INTOLERANCE; GROWTH HORMONE DEFICIENCY; GROWTH HORMONE RELEASE; HIV ASSOCIATED LIPODYSTROPHY; HORMONAL THERAPY; HORMONE ACTION; HORMONE SUBSTITUTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; IMMUNOTOXICITY; INSULIN RESISTANCE; JOINT STIFFNESS; KAPOSI SARCOMA; LEAN BODY WEIGHT; LIPID COMPOSITION; LIPID METABOLISM; LIPID STORAGE; LIPOLYSIS; LONG TERM CARE; LOW DRUG DOSE; MAINTENANCE DRUG DOSE; META ANALYSIS; METABOLIC SYNDROME X; MUSCLE STIFFNESS; MYALGIA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; PHYSICAL CAPACITY; QUALITY OF LIFE; REVIEW; SHORT COURSE THERAPY; SIDE EFFECT; SUBCUTANEOUS FAT; TREATMENT OUTCOME; WASTING SYNDROME;

ANIMALS; HIV INFECTIONS; HIV WASTING SYNDROME; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMAN GROWTH HORMONE; HUMANS;

EID: 27544436203     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.3.5.727     Document Type: Review

References (86)

1. Wanke CA, Silva M, Knox TA, Forrester J, Speigelman D, Gorbach SL. Weight loss and wasting remain common complications in individuals infected with human immunodeficiency virus in the era of highly active antiretroviral therapy. Clin. Infect. Dis. 31, 803-805 (2000).
2. Grinspoon S, Mulligan K; Department of Health and Human Services Working Group on the Prevention and Treatment of Wasting and Weight Loss. Weight loss and wasting in patients infected with human immunodeficiency virus. Clin. Infect. Dis. 36, S69-S78 (2003).
3. Wanke C, Polsky B, Kotler D. Guidelines for using body composition measurement in patients with human immunodeficiency virus infection. AIDS Patient Care STDS 16, 375-388 (2002).
4. Kotler D. Challenges to diagnosis of HIV-associated wasting. J. Acquir. Immune Defic. Syndr. 37, S280-S283 (2004).
5. Parker KL, Schimmer BP. Goodman and Gilman's the Pharmacological Basis of Therapeutics. Hardman JG, Limbird LE (Eds). McGraw Hill, NY, USA, 1541-1549 (2001).
6. Thorner MO, Chapman IM, Gaylinn BD, Pezzoli SS, Hartman ML. Growth hormone-releasing hormone and growth hormone-releasing peptide as therapeutic agents to enhance growth hormone secretion in disease and aging. Recent Prog. Horm. Res. 52, 215-244 (1997).
7. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402, 656-660 (1999).
8. Recombinant human growth hormone. Medical Letter Drugs Therapy 32, 77-78 (1992).
9. Heck AM, Calis KA, Yanovski JA. Pharmacotherapy: A Pathophysiologic Approach. Dipiro JT (Ed.). McGraw Hill, NY, USA, 1288-1291 (1999).
10. de Boer H, van der Veen E. Guidelines for optimizing growth hormone replacement therapy in adults. Horm. Res. 48(Suppl. 5), 21-30 (1997).
11. Drake WM, Coyte D, Camacho-Hubner C et al. Optimizing growth hormone replacement therapy by dose titration in hypopituitary adults. J. Clin. Endocrinol. Metab. 83, 3913-3919 (1998).
12. Voerman HJ, Strack van Schijndel RJ, de Boer H, van der Veen EA, Thijs LG. Growth hormone: secretion and administration in catabolic adult patients, with emphasis on the critically ill patient. Neth. J. Med 41, 229-244 (1992).
13. Koea JB, Breier BH, Douglas RG, Gluckman PD, Shaw JH. Anabolic and cardiovascular effects of recombinant human growth hormone in surgical patients with sepsis. Br. J. Surg. 83, 196-202 (1996).
14. Carroll PV, Van den Berghe G. Safety aspects of pharmacological GH therapy in adults. Growth Horm. IGF Res. 11, 166-172 (2001).
15. Snel YE, Doerga ME, Brummer RM, Zelissen PM, Koppeschaar HP. Magnetic resonance imaging-assessed adipose tissue and serum lipid and insulin concentrations in growth hormone-deficient adults. Effect of growth hormone replacement. Arterioscler. Thromb. 15, 1543-1548 (1995).
16. Bengtsson BA, Eden S, Lonn L et al. Treatment of adults with growth hormone (GH) deficiency with recombinant human GH. J. Clin. Endocrinol. Metab. 76, 309-317 (1993).
17. Cummings DE, Merriam GR. Growth hormone therapy in adults. Annu. Rev. Med. 54, 513-533 (2003).
18. Johannsson G, Marin P, Lorin L et al. Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure. J. Clin. Endocrinol. Metab. 82, 727-734 (1997).
19. Richelsen B, Pedersen SB, Borglum JD, Moller-Pedersen T, Jorgensen J, Jorgensen JO. Growth hormone treatment of obese women for 5 wk: effect on body composition and adipose tissue LPL activity. Am. J. Physiol. 266, E211-E216 (1994).
20. Carroll PV, Christ ER, Bengtsson BA et al. Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. Growth Homone Research Society Scientific Committee. J. Clin. Endocrinol. Metab. 83, 382-395 (1998).
21. Critical evaluation of the safety of recombinant human growth hormone administration: statement from the Growth Hormone Research Society. J. Clin. Endocrinol. Metab. 86, 1868-1870 (2001).
22. Frisch M, Biggar RJ, Engels EA, Goedeft JJ. Association of cancer with AIDS-related immunosuppression in adults. J. Am. Med. Assoc. 285, 1736-1745 (2001).
23. Juul A, Bernasconi S, Carel JC et al. Growth hormone treatment and risk of solid tumours. A statement from the Drugs and Therapeutics Committee of the European Society for Paediatric Endocrinology (ESPE). Horm. Res. 60, 103-104 (2003).
24. Jensen PB, Ekelund B, Nielsen FT, Baumbach L, Pedersen FB, Oxhoj H. Changes in cardiac muscle mass and function in hemodialysis patients during growth hormone treatment. Clin. Nephrol. 53, 25-32 (2000).
25. Lee PD, Pivarnik JM, Bukar JG et al. A randomized, placebo-controlled trial of combined insulin-like growth Factor I and low dose growth hormone therapy for wasting associated with human immunodeficiency virus infection. J. Clin. Endocrinol. Metab. 81, 2968-2975 (1996).
26. Waters D, Danska J, Hardy K et al. Recombinant human growth hormone, insulin-like growth factor 1, and combination therapy in AIDS-associated wasting. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 125, 865-872 (1996).
27. Takala J, Ruokonen E, Webster NR et al. Increased mortality associated with growth hormone treatment in critically ill adults. N. Engl. J. Med. 341, 785-792 (1999).
28. CDC. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR Morb. Mortal. Wkly Rep. 36, 3-15 (1987).
29. Polsky B, Kotler D, Steinhart C. HIV-associated wasting in the HAART era: guidelines for assessment, diagnosis, and treatment. AIDS Patient Care STDS 15, 411-423 (2001).
30. Wheeler DA, Gibert CL, Launer CA et al. Weight loss as a predictor of survival and disease progression in HIV infection. Terry Beirn Community Programs for Clinical Research on AIDS. J. Acquir. Immune Defic. Syndr. 18, 80-85 (1998).
31. Testa MA, Lenderking WR. The impact of AIDS-associated wasting on quality of life: qualitative issues of measurement and evaluation. J. Nutr. 129, 282S-289S (1999).
32. Wilson IB, Roubenoff R, Knox TA, Spiegelman D, Gorbach SL. Relation of lean body mass to health-related quality of life in persons with HIV. J. Acquir. Immune Defic. Syndr. 24, 137-146 (2000).
33. Kotler D. Challenges to diagnosis of HIV wasting. J. Acquir. Immune Defic. Syndr. 37, S280-S283 (2004).
34. Wanke C. Pathogenesis and consequence of HIV wasting. J. Acquir. Immune Defic. Syndr. 37, S277-S279 (2004).
35. Heijligenberg R, Sauerwein HP, Brabant G, Endert E, Hommes MJ, Romijn JA. Circadian growth hormone secretion in asymptomatic human immune deficiency virus infection and acquired immunodeficiency syndrome. J. Clin. Endocrinol. Metab. 81, 4028-4032 (1996).
36. Grinspoon S, Corcoran C, Lee K et al. Loss of lean body and muscle mass correlates with androgen levels in hypogonadal men with acquired immunodeficiency syndrome and wasting. J. Clin. Endocrinol. Metab. 81, 4051-4058 (1996).
37. Lieberman SA, Butterfield GE, Harrison D, Hoffman AR. Anabolic effects of recombinant insulin-like growth factor-I in cachectic patients with the acquired immunodeficiency syndrome. J. Clin. Endocrinol. Metab. 78, 404-410 (1994).
38. Mulligan K, Grunfeld C, Hellerstein MK, Neese RA, Schambelan M. Anabolic effects of recombinant human growth hormone in patients with wasting associated with human immunodeficiency virus infection. J. Clin. Endocrinol. Metab. 77, 956-962 (1993).
39. Krentz AJ, Koster FT, Crist DM et al. Anthropometric, metabolic, and immunological effects of recombinant human growth hormone in AIDS and AIDS-related complex. J. Acquir. Immune Defic. Syndr. 6, 245-251 (1993).
40. Schambelan M, Mulligan K, Grunfeld C et al. Recombinant human growth hormone in patients with HIV-associated wasting. A randomized, placebo-controlled trial. Serostim Study Group. Ann. Intern. Med. 125, 873-882 (1996).
41. Moyle G, Daar E, Gertner J et al. Growth hormone improves lean body mass, physical performance and quality of life in subjects with HIV associated weight loss or wasting on highly active antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 35(4), 367-375 (2004).
42. Tai VW, Schambelan M, Algren H, Shayevich C, Mulligan K. Effects of recombinant human growth hormone on fat distribution in patients with human immunodeficiency virus-associated wasting. Clin. Infect. Dis. 35, 1258-1262 (2002).
43. Mauras N, Horber FF, Haymond MW. Low dose recombinant human insulin-like growth factor-I fails to affect protein anabolism but inhibits islet cell secretion in humans. J. Clin. Endocrinol. Metab. 75, 1192-1197 (1992).
44. Kuzuya H, Matsuura N, Sakamoto M et al. Trial of insulin like growth Factor I therapy for patients with extreme insulin resistance syndromes. Diabetes 42, 696-705 (1993).
45. Mauras N. Combined recombinant human growth hormone and recombinant human insulin-like growth factor I: lack of synergy on whole body protein anabolism in normally fed subjects. J. Clin. Endocrinol. Metab. 80, 2633-2637 (1995).
46. Moyle G, Schoelles K, Farbach K et al. Efficacy of selected treatments of HIV wasting: a systemic review and metaanalysis. J. Acquir. Immune Defic. Syndr. 37, S262-S276 (2004).
47. Daar E, Gaccione P, Muurahainen N, Kotler D, Landy H. Treatment of AIDS wasting with mammalian cell-derived recombinant human growth hormone (r-hGHm) is associated with improved survival. Fifth International Congress on Drug Therapy in HIV Infection. Glasgow, UK (2000).
48. Lo JC, Mulligan K, Tai VW, Algren H, Schambelan M. 'Buffalo hump' in men with HIV-1 infection. Lancet 351, 867-870 (1998).
49. Carr A, Miller J, Law M, Cooper DA. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 12, F51-F58 (1998).
50. Engelson ES, Kotler DP. Tan Y et al. Fat distribution in HIV-infected patients reporting truncal enlargement quantified by whole-body magnetic resonance imaging. Am. J. Clin. Nutr. 69, 1162-1169 (1999).
51. Gripshover B, Tien PC, Saag M et al. Lipoatrophy is the dominant feature of the lipodystrophy syndrome in HIV-infected men. 10th Conference on Retroviruses and Opportunistic Infections. MA, USA (2003).
52. Tien PC, Cole SR, Williams CM et al. Incidence of lipoatrophy and lipohypertrophy in the women's interagency HIV study. J. Acquir. Immune Defic. Syndr. 34, 461-466 (2003).
53. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. J. Am. Med. Assoc. 287, 356-359 (2002).
54. Pouliot MC, Despres JP, Nadeau A et al. Visceral obesity in men. Associations with glucose tolerance, plasma insulin, and lipoprotein levels. Diabetes 41, 826-834 (1992).
55. Zamboni M, Armellini F, Milani MP et al. Evaluation of regional body fat distribution: comparison between W/H ratio and computed tomography in obese women. J. Intern. Med. 232, 341-347 (1992).
56. Fujioka S, Matsuzawa Y, Tokunaga K, Tarui S. Contribution of intra-abdominal fat accumulation to the impairment of glucose and lipid metabolism in human obesity. Metabolism 36, 54-59 (1987).
57. Fujimoto WY, Bergstrom RW, Leonetti DL, Newell-Morris LL, Shuman WP, Wahl PW. Metabolic and adipose risk factors for NIDDM and coronary disease in third-generation Japanese-American men and women with impaired glucose tolerance. Diabetologia 37, 524-532 (1994).
58. Lamarche B. Abdominal obesity and its metabolic complications: implications for the risk of ischaemic heart disease. Coron. Artery Dis. 9, 473-481 (1998).
59. Veldhuis JD, Liem AY, South S et al. Differential impact of age, sex steroid hormones, and obesity on basal versus pulsatile growth hormone secretion in men as assessed in an ultrasensitive chemiluminescence assay. J. Clin. Endocrinol. Metab. 80, 3209-3222 (1995).
60. Ghigo E, Procopio M, Boffano GM et al. Arginine potentiates but does not restore the blunted growth hormone response to growth hormone-releasing hormone in obesity. Metabolism 41, 560-563 (1992).
61. Rietschel P, Hadigan C, Corcoran C et al. Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy. J. Clin. Endocrinol. Metab. 86, 504-510 (2001).
62. Koutkia P, Meininger G, Canavan B, Breu J, Grinspoon S. Metabolic regulation of growth hormone by free fatty acids, somatostatin, and ghrelin in HIV-lipodystrophy. Am. J. Physiol. 286, E296-E303 (2004).
63. Lo JC, Mulligan K, Noor MA et al. The effects of recombinant human growth hormone on body composition and glucose metabolism in HIV-infected patients with fat accumulation. J. Clin. Endocrinol. Metab. 86, 3480-3487 (2001).
64. Saag M, Powderly WG, Schambelan M. Switching antiretroviral drugs for treatment of metabolic complications in HIV-1 infection. Summary of selected trials. Top. HIV Med. 10, 47-51 (2002).
65. Wanke C, Gerrior J, Kantaros J, Coakley E, Albrecht M. Recombinant human growth hormone improves the fat redistribution syndrome (lipodystrophy) in patients with HIV. AIDS 13, 2099-2103 (1999).
66. Torres RA, Unger KW, Cadman JA, Kassous JY. Recombinant human growth hormone improves truncal adiposity and 'buffalo humps' in HIV-positive patients on HAART. AIDS 13, 2479-2481 (1999).
67. Engelson ES, Glesby MJ, Mendez D et al. Effect of recombinant human growth hormone in the treatment of visceral fat accumulation in HIV infection. J. Acquir. Immune Defic. Syndr. 30, 379-391 (2002).
68. Schwarz JM, Mulligan K, Lee J et al. Effects of recombinant human growth hormone on hepatic lipid and carbohydrate metabolism in HIV-infected patients with fat accumulation. J. Clin. Endocrinol. Metab. 87, 942 (2002).
69. Kotler DP, Muurahainen N, Grunfeld C et al. Effects of growth hormone on abnormal visceral adipose tissue accumulation and dyslipidemia in HIV-infected patients. J. Acquir. Immune Defic. Syndr. 35, 239-252 (2004).
70. Andersen O, Haugaard SB, Flyvbierg A et al. Low-dose growth hormone and human immunodeficiency virus-associated lipodystrophy syndrome: a pilot study. Eur. J. Clin. Invest. 34, 561-568 (2004).
71. Lo JC, Mulligan K, Noor MA et al. The effects of low dose growth hormone in HIV-infected men with fat accumulation: a pilot study. Clin. Infect. Dis. 39, 732-735 (2004).
72. Falutz J, Allas S, Kotler D et al. A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation. AIDS 19, 1279-1287 (2005).
73. Snyder DK, Underwood LE, Clemmons DR. Anabolic effects of growth hormone in obese diet-restricted subjects are dose-dependent. Am. J. Clin. Nutr. 52, 431-437 (1990).
74. Laurence J, Grimison B, Gonenne A. Effect of recombinant human growth hormone on acute and chronic human immunodeficiency virus infection in vitro. Blood 79, 467-472 (1992).
75. Koutkia P, Canavan B, Breu J, Torriani M, Kissko J, Grinspoon S. Growth hormone-releasing hormone in HIV-infected men with lipodystrophy: a randomized controlled trial. J. Am. Med. Assoc. 292, 210-218 (2004).
76. Murray RD. Adult growth hormone replacement: current understanding. Curr. Opin. Pharm. 3, 642-649 (2003).
77. Rahim A, O'Neill PA, Shalet SM. Growth hormone status during long-term hexarelin therapy. J. Clin. Endocrinol. Metab. 83, 572-580 (1998).
78. Svensson J, Monson JP, Velter T et al. Oral administration of the growth hormone secretagogue NN703 in adult patients with growth hormone deficiency. Clin. Endocrinol. 58, 572-580 (2003).
79. Paton NI, Newton PJ, Sharpstone DR et al. Short-term growth hormone administration at the time of opportunistic infections in HIV-positive patients. AIDS 13, 1195-1202 (1999).
80. Bonyhadi ML, Rabin L, Salimi S et al. HIV induces thymus depletion in vivo. Nature 363, 728-732 (1993).
81. Su L, Kaneshima H, Bonyhadi M et al. HIV-1-induced thymocyte depletion is associated with indirect cytopathogenicity and infection of progenitor cells in vivo. Immunity 2, 25-36 (1995).
82. McCune JM. The dynamics of CD4+ T-cell depletion in HIV disease. Nature 410, 974-979 (2001).
83. Napolitano LA, Lo JC, Gotway MB et al. Increased thymic mass and circulating naive CD4 T cells in HIV-1-infected adults treated with growth hormone. AIDS 16, 1103-1111 (2002).
84. Nguyen BY, Clerici M, Venzon DJ et al. Pilot study of the immunologic effects of recombinant human growth hormone and recombinant insulin-like growth factor in HIV-infected patients. AIDS 12, 895-904 (1998).
85. Jager H, Knechten H, Moll A, Weimer L, Fischer H, Schmitt-Rau K. Treatment of HIV-associated wasting with recombinant human growth hormone: monitoring of body composition changes by bioelectrical impedance analysis (BIA). Eur. J. Med. Res. 7, 103-108 (2002).
86. He Q, Engelson ES, Albu JB, Heymsfield SB, Kotler DP. Preferential loss of omental-mesenteric fat during growth hormone therapy of HIV-associated lipodystrophy. J. Appl. Physiol. 94, 2051-2057 (2003).